We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Advisory Committee to Review Merck's Arcoxia

FDA Advisory Committee to Review Merck's Arcoxia

April 11, 2007

An increased risk of side effects from Merck's potential Vioxx successor Arcoxia indicates the drug should not be approved unless it fills an unmet need, an FDA employee told an advisory committee.

Studies of Arcoxia (etoricoxib) show the drug may increase the risk of high blood pressure and congestive heart failure, but it is as effective as diclofenac in treating arthritis pain, the FDA said.

The agency released reviews of several Arcoxia studies prior to the April 12 meeting of the FDA's Arthritis Advisory Committee to discuss the drug. A large Merck study showed Arcoxia had similar rates of adverse cardiovascular events as diclofenac. However, other smaller studies showed the drug had a higher risk of cardiovascular events than naproxen or a placebo, the FDA said.

In addition, patients in one study taking Arcoxia dropped out at a higher rate because of high blood pressure problems, the agency said. Merck said the risks with Arcoxia are "consistent" with other Cox-2 inhibitors.

Merck also said the drug was less likely to cause gastrointestinal problems than other nonsteroidal anti-inflammatory drugs. However, the FDA's analysis said Arcoxia and diclofenac had similar rates of gastrointestinal problems.

A new product with an increased risk for cardiovascular disease should not be approved unless it serves an unfilled need, Bob Rappaport, director of CDER's Division of Anesthesia, Analgesic and Rheumatology Products, said in a letter to the committee. He warned against approving Arcoxia if it did not show a "reasonable risk to benefit balance" for a patient population lacking safe, approved treatments.

However, a former FDA employee said approving an effective Cox-2 inhibitor pain treatment is important because not all patients respond the same way to medications. "Some patients respond and some patients don't -- so having a choice is very important," former director of CDER's Analgesic, Anti-Inflammatory and Ophthalmologic Drug Product Division Lee Simon said. ( http://www.fdanews.com/did/6_72/ )

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing